NASDAQ
20.03.26 | 20:50
2,700 US-Dollar
+3,45 % +0,090
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.03. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| 26.02. | Barclays raises C4 Therapeutics stock price target on trial progress | 9 | Investing.com | ||
| 26.02. | TD Cowen reiterates Buy rating on C4 Therapeutics stock | 1 | Investing.com | ||
| 26.02. | TD Cowen bestätigt "Buy"-Rating für C4 Therapeutics nach starkem Kursanstieg | 2 | Investing.com Deutsch | ||
| 26.02. | C4 Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| C4 THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 26.02. | C4 Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 26.02. | C4 Therapeutics beats Q4 street views | 1 | Seeking Alpha | ||
| 26.02. | Earnings Summary: C4 Therapeutics Q4 | 1 | Benzinga.com | ||
| 26.02. | C4 Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 23.02. | Brookline Capital raises C4 Therapeutics stock price target on trial progress | 2 | Investing.com | ||
| 23.02. | C4 Therapeutics: Erster Patient in Phase-2-Studie zu Multiplem Myelom behandelt | 2 | Investing.com Deutsch | ||
| 23.02. | C4 Therapeutics, Inc.: C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma | 230 | GlobeNewswire (Europe) | Enrollment for Phase 2 MOMENTUM Trial Expected to Be Completed in Q1 2027 Phase 1b Trial of Cemsidomide in Combination with Elranatamab on Track to Initiate in Q2 2026 WATERTOWN, Mass., Feb. 23,... ► Artikel lesen | |
| 20.02. | Strong Analyst Confidence in C4 Therapeutics (CCCC)'s Cemsidomide Drives 270% Upside Potential | 1 | Insider Monkey | ||
| 09.02. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 04.02. | C4 Therapeutics, Inc.: C4 Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026 | 1 | GlobeNewswire (USA) | ||
| 26.01. | C4 Therapeutics, Inc.: C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 1 | GlobeNewswire (USA) | ||
| 14.01. | C4 Therapeutics, Inc.: C4 Therapeutics Outlines Strategic Milestones to Advance Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader and Discovery Strategy Focused on Novel Targets in Clinically Validated Pathways | 414 | GlobeNewswire (Europe) | Cemsidomide Phase 2 MOMENTUM Trial On Track to Initiate in Q1 2026; Recommended Phase 2 Dose is 100 µg Cemsidomide Phase 1b Trial in Combination With Elranatamab On Track to Initiate in Q2 2026 Internal... ► Artikel lesen | |
| 14.01. | C4 Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 02.12.25 | C4 Therapeutics: TD Cowen startet Coverage mit Kaufempfehlung | 5 | Investing.com Deutsch | ||
| 02.12.25 | C4 Therapeutics stock initiated with Buy rating at TD Cowen | 3 | Investing.com |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| OCUGEN | 1,759 | +1,24 % | Ocugen, Inc. - 8-K, Current Report | ||
| INOVIO PHARMACEUTICALS | 1,400 | 0,00 % | H.C. Wainwright reiterates Inovio stock rating on FDA review | ||
| CELLDEX THERAPEUTICS | 26,800 | 0,00 % | Celldex Therapeutics, Inc.: Celldex Presents Additional Positive Data from Phase 2 Chronic Spontaneous Urticaria (CSU) and Phase 2 Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Studies Further Demonstrating First-in-Class and Best-in-Disease . | - Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients with CSU treated for full 52 weeks -- Greatly improved... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 1,540 | -0,90 % | Cardiff Oncology, Inc.: Cardiff Oncology to Host Key Opinion Leader Discussion Focusing on First-Line RAS-mutated Metastatic Colorectal Cancer | ||
| COHERUS ONCOLOGY | 1,349 | +2,94 % | Coherus Oncology, Inc.: Coherus Oncology Reports Full Year and Fourth Quarter 2025 Financial Results and Provides Business Update | - LOQTORZI net revenue more than doubled to $40.8 million in 2025 from $19.1 million in 2024 - - Reduced secured and convertible debt by 90% from $480 million to $38.8 million over 2024-2025 - - $172.1... ► Artikel lesen | |
| ARCTURUS THERAPEUTICS | 6,640 | -1,34 % | Cathie Wood's ARK adds 10x Genomics stock, trims Arcturus | ||
| GYRE THERAPEUTICS | 6,700 | +14,53 % | Gyre Therapeutics Inc.: Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Full-year 2025 revenue increased 10% year-over-year to $116.6 million, within revised guidance range Full year 2026 revenue guidance of $100.5 to $111.0 million Entered into agreement to acquire Cullgen... ► Artikel lesen | |
| ULTRAGENYX | 17,100 | 0,00 % | Ultragenyx Pharmaceutical Inc.: Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | ||
| SAGIMET BIOSCIENCES | 4,200 | -1,41 % | Sagimet Biosciences Inc.: Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates | Completed Phase 1 pharmacokinetic (PK) clinical trial of denifanstat and resmetirom combination Phase 2 trial of denifanstat/resmetirom combination in F4 MASH patients planned to initiate in 2H 2026... ► Artikel lesen | |
| GOSSAMER BIO | 0,350 | -0,96 % | Gossamer Bio: EPS verfehlt Schätzungen um 0,02 $ - Umsatz besser als erwartet | ||
| BIOMEA FUSION | 1,125 | +2,27 % | Biomea Fusion Reports Positive Phase II Data For Diabetes Drug Icovamenib | ||
| JANUX THERAPEUTICS | 14,040 | -0,78 % | Morning Market Movers: Taoping, Janux Therapeutics, MongoDB, American Bitcoin Corp. See Big Swings | CANBERA (dpa-AFX) - At 7:25 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SOLID BIOSCIENCES | 7,030 | -1,33 % | Solid Biosciences Inc.: Solid Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates | - Duchenne (SGT-003): Positive interim Phase 1/2 INSPIRE DUCHENNE data reported at the 2026 MDA Annual Meeting continued to suggest differentiated clinical, safety and tolerability profiles; SGT-003... ► Artikel lesen | |
| 4D MOLECULAR THERAPEUTICS | 8,620 | -3,69 % | 4D Molecular Therapeutics, Inc.: 4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones | Completed enrollment in 4D-150 4FRONT-1 wet AMD Phase 3 trial within approximately 11 months, ahead of initial projections and reflecting strong interest from investigators and patients; topline data... ► Artikel lesen | |
| TENAYA THERAPEUTICS | 0,751 | -6,53 % | Tenaya Therapeutics, Inc.: Tenaya Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Reported Promising Data for TN-201 and TN-401 Gene Therapies in Fourth Quarter of 2025; Additional Data Readouts and Pursuit of Regulatory Alignment for Each Program Planned in 2026 New Research Supports... ► Artikel lesen |
C4 THERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 2,700 Euro und damit +3,45 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu C4 THERAPEUTICS INC finden Sie auf Wallstreet Online.